A(2A) adenosine receptors in human peripheral blood cells

British Journal of Pharmacology

Volumn 129, Issue 1, 2000, Pages 2-11

  Gessi, S ^a   Varani, K ^a   Merighi, S ^a   Ongini, E ^b   Borea, P A ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b San Raffaele Science Park   (Italy)

Author keywords

A(2A) adenosine receptors; Lymphocytes; Neutrophils; Platelets

Indexed keywords

2 ANILINOADENOSINE; 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 8 [4 (2 AMINOETHYLCARBAMOYL)METHOXYPHENYL] 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; CAFFEINE; CYCLOHEXYLADENOSINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; PHENYLISOPROPYLADENOSINE; SCH 59765; THEOPHYLLINE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL CELL; BINDING AFFINITY; CORPUS STRIATUM; HUMAN; HUMAN CELL; LYMPHOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE;

EID: 0033970029     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703045     Document Type: Review

References (101)

1. Abbracchio, M.P. & Burnstock, G. (1998). Purinergic signalling: pathophysiological roles. Jpn. J. Pharmacol., 78, 113-145.
2. Alexander, S.P.H. & Peters, J.A. (1997). Receptor & Ion Channel Nomenclature Supplement, Adenosine receptors. Trends Pharmacol. Sci. 10, (Suppl.), 7-8.
3. Apasov, S., Koshiba, M., Chused, T.M. & Sitkovsky, M. (1997). Effects of extracellular ATP and adenosine on different thymocytes subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor. J. Immunol., 158, 5095-5105.
4. 2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett., 4, 2539-2544.
5. Barbieri, D., Abbracchio, M.P., Salvioli, S., Monti, D., Cossarizza, A., Ceruti, S., Brambilla, R., Cattabeni, F., Jacobson, K.A. & Franceschi, C. (1998). Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem. Int., 32, 493-504.
6. Becker, B.F., Zahler, S., Raschke, P., Schwartz, L.M. & Beblo, S. (1992). Adenosine enhances neutrophil sticking in the coronary system: a novel mechanism contributing to cardiac reperfusion damage. Pharm. Pharmacol. Lett., 2, 8-11.
7. Belardinelli, L., Linden, J. & Berne, R.M. (1989). The cardiac effects of adenosine. Prog. Cardiovasc. Dis., 32, 73-97.
8. 3H]-SCH 58261 to coronary artery membranes. Circ. Res., 79, 1153-1160.
9. Blackburn, M.R., Datta, S.K., Wakamiya, M., Vartabedian, B.S. & Kellems, R.E. (1996). Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J. Biol. Chem., 271, 15203-15210.
10. Bonnafous, J.C., Dornand, J., Favero, J. & Mani, J.C. (1981). Lymphocyte membrane adenosine receptors coupled to adenylate cyclase properties and occurrence in various lymphocyte subclasses. J. Receptor Res., 2, 347-366.
11. 2A receptor ligands. Biochem. Pharmacol., 49, 461-469.
12. Born, G.V.R. & Cross, M.J. (1963). The aggregation of blood platelets. J. Physiol., 168, 178-195.
13. 3 receptors. J. Immunol., 158, 5400-5408.
14. 3H]-NECA in rat striatal membranes. Mol. Pharmacol., 29, 331-346.
15. Burkey, T.H. & Webster, R.O. (1993). Adenosine inhibits FMLP-stimulated adherence and superoxide anion generation by human neutrophils at an early step in signal transduction. Biochim. Biophys. Acta, 1175, 312-318.
16. Carrera, J.C., Saven, A. & Piro, L.D. (1994). Purine metabolism of lymphocytes. New Drug Therapy, 8, 357-380.
17. Crabtree, GR. (1989). Contingent genetic regulatory events in T lymphocyte activation. Science, 243, 355-361.
18. Cristalli, G., Vittori, S., Thompson, R.D., Padgett, W.L., Shi, D., Daly, J.W. & Olsson, R.A. (1994). Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn. Schmied. Arch. Pharmacol., 349, 644-650.
19. Cronstein, B.N. (1994). Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76, 5-13.
20. Cronstein, B.N. (1995). A novel approach to the development of antiinflammatory agents: Adenosine release at the inflammed sites. J. Invest. Med., 43, 50-57.
21. Cronstein, B.N. (1997). Adenosine regulation of neutrophil function and inhibition of inflammation via adenosine receptors. In: Jacobson, K.A. & Jarvis, M.F (eds). Purinergic Approaches in Experimental Therapeutics, pp. 285-299. New York: Wiley-Liss, Inc.
22. 2 generation, respectively. J. Clin. Invest., 85, 1150-1157.
23. 2-receptor occupancy inhibits the sustained but not the early, events of stimulus transduction in human neutrophils by a mechanism independent of actin-filament formation. Biochem. J., 281, 631-635.
24. Cronstein, B.N., Haines, K.A., Kolasinski, S. & Reibman, J. (1992b). Occupancy of G alpha s-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil. Blood, 80, 1052-1057.
25. Cronstein, B.N., Kramer, S.B., Rosenstein, E.D., Korchak, H.M., Weissmann, G. & Hirschhorn, R. (1988). Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Biochem. J., 252, 709-715.
26. Cronstein, B.N., Kramer, S.B., Weissman, G. & Hirschhorn, R. (1983). Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J. Exp. Med., 158, 1160-1177.
27. 2 receptors. J. Immunol., 148, 2201-2206.
28. 2 receptor on human neutrophils. J. Immunol., 135, 1366-1371.
29. Cronstein, B.N. & Weissmann, G. (1993). The adhesion molecules of inflammation. Arthritis Rheum., 36, 147-157.
30. Daly, J.W., Bruns, R.F. & Snyder, S.H. (1981). Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines. Life Sci., 28, 2083-2097.
31. 3H]adenosine binding to pig aorta smooth muscle membranes. Biochem. Pharmacol., 36, 3621-3627.
32. 2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models. Br. J. Pharmacol., 112, 659-665.
33. 3H]-SCH 58261. J. Pharmacol. Exp. Ther., 298, 726-732.
34. 3H]-SCH 58261. Br. J. Pharmcol., 121, 353-360.
35. Dionisotti, S., Zocchi, C., Varani, K., Borea, P.A. & Ongini, E. (1992). Effects of adenosine derivatives on human and rabbit platelet aggregation. Correlation of adenosine receptor affinities and antiaggregatory activity. Naunyn Schmied. Arch. Pharmacol., 346, 673-676.
36. Fein, T., Schulze, E., Bar, J. & Schwabe, U. (1994). Purification and characterization of an adenotin-like adenosine binding protein from human platelets. Naunyn. Schmied. Arch. Pharmacol., 349, 374-380.
37. Fong, Y. & Lowry, S.F. (1990). Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin. Immunol. Immunopathol., 55, 157.
38. Fredholm, B.B., Abbracchio, M.P., Burnstock, G., Daly, J.W., Harden, T.K., Jacobson, K.A., Leff, P. & Williams, M. (1994). Nomenclature and classification of purinoceptors. Pharmacol. Rev., 46, 143-156.
39. 2A receptor antagonist, is a useful ligand in autoradiographic studies. J. Neurochem., 70, 1210-1216.
40. 2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leukocytes. Naunyn. Schmied. Arch. Pharmacol., 354, 262-267.
41. Gadangi, P., Longaker, M., Naime, D., Levin, R.I., Recht, P.A., Carlin, G. & Cronstein, B.N. (1996). The antiinflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol., 156, 1937-1941.
42. Giblett, E.R., Anderson, J.E., Cohen, F., Pollara, B. & Meuwissen, H.J. (1972). Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet, 2, 1067-1069.
43. Gilli, P., Ferretti, V., Gilli, G. & Borea, P. A. (1994). Enthalpyentropy compensation in drug-receptor binding. J. Phys. Chem., 98, 1515-1518.
44. Haslam, R.J. & Cusack, N.J. (1981). Blood platelet receptors for ADP and for adenosine. In: Burnstock G (ed) Purinergic receptors. Chapman & Hall, London New York, 223-285.
45. Hirschorn, R. (1995). Adenosine deaminase deficiency: molecular basis and recent developments. Clin. Immumol. Immunopathol., 76 Pt 2, S219-227.
46. 2 cell-surface adenosine receptor. Cell. Immunol., 159, 85-93.
47. 2A extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood, 90, 1600-1610.
48. Hutchison, K. A., Nervis, B., Perini, F. & Fox, I. H. (1990). Soluble and membrane-associated human low-affinity adenotin binding protein (adenolin): properties and homology with mammalian and avian stress proteins. Biochemistry, 29, 5138-5144.
49. 3H]adenosine binding in relation to adenylate cyclase activity. Naunyn. Schmied. Arch. Pharmacol., 325, 226-233.
50. Jacobson, K.A., Van Galen, P.J.M. & Williams, M. (1992). Perspective, adenosine receptors: Pharmacology, structure activity relationships and therapeutic potential. J. Med. Chem., 35, 407-22.
51. Jacobson, M.A. (1995). Molecular biology of adenosine receptors. In: Belardinelli, L., & Pelleg, A. (eds). Adenosine and adenine nucleotides: from molecular biology to integrative physiology. pp. 241-248. Boston, U.S.A.: Kluwer Academic Publishers.
52. 2 receptors in rat brain. J. Pharmacol. Exp. Ther., 251, 888-893.
53. Jesaitis, A.J., Tolley, J.O., Bokock, G.M. & Allen, R.A. (1989). Regulation of chemoattractant receptor interaction with transducing proteins by organizational control in the plasma membrane of human neutrophils. J. Cell. Biol., 109, 2783-2790.
54. 2 receptors in rat striatum. Biochem Pharmacol., 44, 2365-2370.
55. 2 receptor. Biochem. Pharmacol., 21, 3827-3833.
56. 2A purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem., 272, 25881-25889.
57. 2A receptor monoclonal antibodies. Mol. Pharmacol., 55, 614-624.
58. 2A receptor. Nature, 388, 674-678.
59. 3 receptors: pharmacological properties, species differences and receptor functions. Trends. Pharmacol. Sci., 15, 298-306.
60. 3H]-NECA hinding sites by gel filtration. Naunyn Schmied. Arch. Pharmacol., 337, 64-68.
61. Londos, C., Cooper, M.F.D. & Wolff, J. (1980). Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci., 77, 2551-2554.
62. 3 receptor. Cancer. Res., 54, 3521-3526.
63. Marone, G., Plaut, M. & Lichtenstein, L.M. (1978). Characterization of a specific adenosine receptor on lymphocytes. J. Immunol., 121, 2153-2159.
64. Marts, B.C., Baudendistel, L.J., Naunheim, K.S. & Dahms, T.E. (1993). Protective effect of 2-chloroadenosine on lung ischemia reperfusion injury. J. Surg. Res., 54, 523.
65. 2A adenosine receptor agonist CGS 21680C in conscious normotensive rats. Br. J. Pharmacol., 114, 761-768.
66. Nakata, H. & Fujisawa, H. (1988). Adenosine binding sites of rat pheochromocytoma PC 12 cell membranes: partial characterization and solubilization. J. Biochem., 104, 457-460.
67. 2 receptor. Naunyn. Schmied. Arch. Pharmacol., 347, 234-237.
68. Olah, M.E. & Stiles, G.L. (1995). Adenosine receptor subtypes: Characterization and Therapeutic Regulation. Ann. Rev. Pharmacol. Toxicol., 35, 581-606.
69. Ongini, E., Dionisotti, S., Gessi, S., Irenius, E. & Fredholm, B. B. (1999). Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn. Schmied. Arch. Pharmacol., 359, 7-10.
70. 2A receptors. Trends Pharmacol. Sci., 17, 364-372.
71. Pasini, F.L., Capecchi, P.L., Orrico, A., Ceccatelli, L. & Dipierri, T. (1985). Adenosine inhibits polymorphonuclear leukocyte in vitro activation: a possible role as an endogenous calcium entry blocker. Int. J. Immunopharmol., 7, 203-215.
72. Paul, S., Feoktistov, I., Hollister, A.S., Robertson, D. & Biaggioni, I. (1990). Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: evidence that both effects are coupled to adenylate cyclase. Mol. Pharmacol., 37, 870-875.
73. Poulsen, S-A. & Quinn, R.J. (1998). Adenosine receptors: new opportunities for future drugs. Bioorg. & Med. Chem., 6, 619-641.
74. Ralevic, V. & Burnstock, G. (1998). Receptors for purines and pyrimidines. Pharmacol. Reviews, 50, 413-492.
75. 2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonin protein phosphate. J. Biol. Chem., 271, 17114-17118.
76. Salmon, J.E. & Cronstein, B.N. (1990). Fcg-receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. J. Immunol., 145, 2235-2240.
77. Schrier, D.J. & Imre, K.M. (1986). The effects of adenosine on human neutrophil function. J. Immunol., 137, 3284-3289.
78. Schultz, L.A., Kammer, G.M. & Rudolph, S.A. (1988). Characterization of the human T lymphocyte adenosine receptor: comparison of normal and systemic lupus erythematosus cells. FASEB J., 2, 244-250.
79. Schwartz, L.M., Raschke, P., Becker, B.F. & Gerlach, E. (1993). Adenosine contributes to neutrophil-mediated loss of myocardial function in postischemic guinea pig hearts. J. Mol. Cell. Cardiol., 25, 927-938.
80. Schwartz, L.M., Stern, R.C. & Polmar, S.H. (1978). Demonstration of an adenosine receptor on human lymphocytes in vitro and its possible role in the adenosine deaminase-deficient form of severe combined immunodeficiency. Clin. Immunol. Immunopathol., 9, 499-505.
81. Seekamp, A., Warren, J.S., Remick, D.G., Till, G.O. & Ward, P.A. (1993). Requirements for tumor necrosis factor-a and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am. J. Pathol., 143, 453.
82. Smith, P.T., Armstrong, J., Koshiba, M., Huang, S., Apasov, S. & Sitkovsky, M. (1998). Studies of expression and possible functional role of purinergic receptors in cell-mediated immunity: experimental approaches, controls, and caveats. Drug. Dev. Res., 45, 229-244.
83. Sitkovsky, M.V. (1998). Extracellular purines and their receptors in immunoregulation. Review of recent advances. Nippon Ika Daigaku Zasshi, 65, 351-357.
84. Stiles, G.L. & Jacobson, K.A. (1987). A new affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol. Pharmacol., 32, 184-188.
85. Sullivan, G.W., Carper, H.T. & Mandell, G.L. (1995). The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-α-primed neutrophil oxidative activity. Int. J. Immunopharmacol., 17, 793-803.
86. 2A adenosine receptors in inflammation. Drug Dev. Res., 45, 103-112.
87. Sullivan, G., Linden, J., Hewlett, E., Carper, H., Hylon, J., & Mandell, G. (1990). Adenosine and related compounds counteract tumor necrosis factor-alpha inhibition of neutrophil migration: implication of a novel cyclic AMP-independent action on the cell surface. J. Immunol., 145, 1537-1544.
88. Thiel, M. & Bardenheuer, H. (1992). Regulation of oxygen radical production of human polymorphonuclear leukocytes by adenosine: the role of calcium. Pfluegers Arch., 420, 522-528.
89. Ukena, D., Bohme, E. & Schwabe, U. (1984). Effects of several 5'-carboxamide derivatives of adenosine on adenosine receptors of human platelets and rat fat cells. Naunyn. Schmied. Arch. Pharmacol., 327, 36-42.
90. 2 adenosine receptors of human platelets. FEBS Lett., 199, 269-274.
91. 3H]-CGS 21680 to human platelet membranes. Biochem. Pharmacol., 48, 1658-1661.
92. 3H] CGS 21680 binding. Br. J. Pharmacol., 117, 1693-1701.
93. 3H] SCH 58261 binding. Br. J. Pharmacol., 122, 386-392.
94. 2A adenosine receptors in human neutrophil membranes. Br. J. Pharmacol., 123, 1723-1731.
95. 2A receptors of human circulating blood elements. Drug Dev. Res., 45, 253-260.
96. Waldmann, T.A. (1986). The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science, 232, 727-732.
97. Wolberg, G., Zimmerman, T.P., Hiemstra, K., Winston, M. & Chu, L.C. (1975). Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate. Science, 87, 957-959.
98. i adenosine receptors in striatum. Naunyn. Schmied. Arch. Pharmacol., 325, 218-225.
99. 2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther., 276, 398-404.
100. 2A adenosine receptor antagonist, to rat striatal membranes. Br. J. Pharmacol., 117, 1381-1386.
101. 2-like binding protein. Mol. Pharmacol., 37, 554-559.